Criteria for defining risk groups in stages I/II Hodgkin lymphoma.
Trial group . | Risk group . | Criteria . |
---|---|---|
EORTC | Favorable | One or two nodal areas and |
No mediastinal bulk (mass > 0.35 of thoracic diameter at level of D5-6) and | ||
In the prescence of B symptoms, ESR < 30 | ||
or in the absence of B symptoms, ESR < 50 | ||
Unfavorable | Any of the above risk factors present | |
GHSG | Favorable | One or two nodal areas and |
No mediastinal bulk and | ||
No extra-nodal disease and | ||
In the prescence of B symptoms, ESR < 30 | ||
or in the absence of B symptoms, ESR < 50 | ||
Age 75 years or less | ||
Unfavorable | Any of the above risk factors present | |
NCI (Canada) and ECOG | Exclude high risk | Bulky mediastinal involvement or |
Intra-abdominal disease | ||
Exclude low risk | Stage IA with single node involved in high neck or epitrochlear regions only and | |
Lymphocyte predominant or nodular sclerosing histology and | ||
Bulk < 3 cm and | ||
ESR < 50 | ||
Remainder categorized as favorable or unfavorable. | ||
Unfavorable patients have any of | Age ≥ 40 | |
ESR ≥ 50 | ||
Mixed cellularity or lymphocyte-depleted histology | ||
≥ 4 sites of disease |
Trial group . | Risk group . | Criteria . |
---|---|---|
EORTC | Favorable | One or two nodal areas and |
No mediastinal bulk (mass > 0.35 of thoracic diameter at level of D5-6) and | ||
In the prescence of B symptoms, ESR < 30 | ||
or in the absence of B symptoms, ESR < 50 | ||
Unfavorable | Any of the above risk factors present | |
GHSG | Favorable | One or two nodal areas and |
No mediastinal bulk and | ||
No extra-nodal disease and | ||
In the prescence of B symptoms, ESR < 30 | ||
or in the absence of B symptoms, ESR < 50 | ||
Age 75 years or less | ||
Unfavorable | Any of the above risk factors present | |
NCI (Canada) and ECOG | Exclude high risk | Bulky mediastinal involvement or |
Intra-abdominal disease | ||
Exclude low risk | Stage IA with single node involved in high neck or epitrochlear regions only and | |
Lymphocyte predominant or nodular sclerosing histology and | ||
Bulk < 3 cm and | ||
ESR < 50 | ||
Remainder categorized as favorable or unfavorable. | ||
Unfavorable patients have any of | Age ≥ 40 | |
ESR ≥ 50 | ||
Mixed cellularity or lymphocyte-depleted histology | ||
≥ 4 sites of disease |